Tag: GlobeNewswire

Solution combines digital power control, GaN technology, and hardware-based security to accelerate development of high-efficiency rack power systems based on the 800V DC OCP standard

TORRANCE, Calif. and CHANDLER, Ariz., Oct. 05, 2026 (GLOBE NEWSWIRE) — Navitas Semiconductor (Nasdaq: NVTS) and Microchip Technology (Nasdaq: MCHP) – As AI data centers scale to support high-power GPU clusters, the industry is shifting toward 800V DC rack power architectures to improve distribution efficiency, increase power density and support next-generation server designs. To help accelerate this transition, Navitas and Microchip have collaborated on an 800V DC-to-6V DC reference design for AI data center rack power applications.

The platform combines Microchip’s digital power control and security technologies with Navitas’ GaNFast™ gallium nitride (GaN) power devices to give developers a practical path to implement high-efficiency power conversion aligned with the Open Compute Project (OCP) 800V DC standard. Complete with reference hardware, software and design documentation, the solution helps reduce design risk, shorten development cycles and accelerate deployment of next-generation AI infrastructure.

“AI infrastructure optimization is driving one of the most significant power architecture transitions the data center industry has experienced in decades,” said Joe Thomsen, corporate vice president of Microchip’s digital signal controller business unit. “As the ecosystem moves toward higher-voltage rack power systems, developers need proven building blocks that help reduce design risk and accelerate innovation. Our collaboration with Navitas brings together complementary technologies to help customers navigate this transition and bring next-generation power solutions to market more quickly.”

At the core of the reference platform are Microchip’s dsPIC33AK Digital Signal Controllers (DSCs), TA100 CryptoAuthentication™ device, and Navitas’ GaNFast FETs. The dsPIC33AK is designed to provide high-resolution control, high-speed analog and security with support for post-quantum cryptography. The devices offer library support for Commercial National Security Algorithm (CNSA) Suite 2.0 recommended post-quantum cryptographic (PQC) algorithms and feature hardware accelerated cryptographic functions needed in Open Compute Project (OCP) power supplies and other connected real-time control designs. Powered by a 200 MHz 32-bit core with a double-precision floating-point unit (FPU), the dsPIC33AK256MPS306 family combines 78 ps high-resolution Pulse Width Modulators (PWMs) and multiple 12-bit Analog-to-Digital Converters (ADCs) operating at up to 40 MSPS. The high-speed core and peripherals support fast, deterministic control loops for high frequency, high-efficiency DC/DC power conversion.

This PDB is powered by 16 × NV6034, 650 V, 17 mΩ GaNFast FETs in a stacked half-bridge topology on the primary side. The DFN8×8 dual-side-cooled package extends the performance advantages of GaN by reducing thermal resistance, allowing higher continuous power operation while maintaining exceptional efficiency. The PDB targets delivering up to 96% peak efficiency at full load with 1 MHz switching frequency, enabling a power density of 2,100 W/in³.

Approximately 20% thinner than a mobile phone, its ultra-low profile enables extremely close integration with the GPU board, maximizing transient performance and improving power distribution efficiency. Navitas’ system-level approach ensures that advances in GaN technology translate into measurable improvements in efficiency, power density, transient performance, and total cost of ownership. Direct conversion from 800V DC to 6V DC combines both 800V DC to 50V DC and 50V DC to 6V DC conversion stages into one converter, delivering higher end-to-end efficiency.

“As AI infrastructure scales to support increasingly demanding computing platforms, Navitas’ GaNFast technology is a critical enabler of higher power density, greater efficiency, and improved system performance,” said Vipin Bothra, vice president of Global Solution Marketing at Navitas Semiconductor. “By combining Navitas’ leadership in power semiconductors with Microchip’s digital control expertise, this collaboration accelerates the delivery of advanced power solutions tailored to the evolving requirements of next-generation AI data centers.”

The reference design also incorporates Microchip’s TA100 CryptoAuthentication™ device to help address growing security requirements within modern power infrastructure. By integrating hardware-based security into the design, developers can establish a trusted foundation for system authentication and protection without the complexity of implementing security measures from scratch. The TA100 device provides support for code authentication (secure boot), Message Authentication Code (MAC) generation, trusted firmware updates, multiple key management protocols including Transport Layer Security (TLS) and other root-of-trust-based operations.

The Microchip and Navitas reference design provides a platform for developing high-voltage, high power, compact rack power systems for AI data centers. The design combines power control, security and GaN power technologies to support efficient 800V-to-6V-power conversion while helping system developers address evolving power delivery, performance and form-factor requirements. The solution will be showcased at Microchip’s OCP Event, taking place October 12–15, 2026, in San Jose, California.

The design will be supported with a reference board, software and supporting documentation, giving developers access to the resources needed to evaluate and accelerate deployment of 800V DC power conversion systems for AI data center applications.

About Navitas
Navitas Semiconductor (Nasdaq: NVTS) is a next-generation power semiconductor leader in gallium nitride (GaN) and integrated-circuit devices, and high-voltage silicon carbide (SiC) technology. Navitas drives innovation across AI Infrastructure, combining Grid and Energy Infrastructure and AI data centers, as well as Performance Computing and Industrial Electrification. With more than 30 years of combined expertise in wide-bandgap technologies, GaNFast™ power ICs integrate GaN power, drive, control, sensing and protection to deliver faster power delivery, higher system density and greater efficiency. GeneSiC™ high-voltage SiC devices leverage patented Trench-Assisted Planar technology to provide industry-leading voltage capability, efficiency and reliability for medium-voltage grid and infrastructure applications. Navitas has more than 300 patents issued or pending and is the world’s first semiconductor company to be CarbonNeutral® certified.

Navitas Semiconductor, GaNFast, GaNSense, GaNSafe, GeneSiC, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited or affiliates. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

About Microchip Technology
Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. CryptoAuthentication is a trademark of Microchip Technology Inc. in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Contact Information
Navitas Semiconductor
Vipin Bothra
info@navitassemi.com

Microchip Technology
Amber Liptai    
480-792-5047    
Amber.liptai@microchip.com

Navitas Investors Contact
Leanne Sievers | Brett Perry
Shelton Group
sheltonir@sheltongroup.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are attempts to predict or indicate future events or trends or similar statements that are not a reflection of historical fact. Forward-looking statements are not predictions of actual future performance. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions and expectations. Microchip’s risks are discussed in its most recent annual report on Form 10-K, as updated in its most recent quarterly report on Form 10-Q, and other documents filed with the SEC. For Navitas, these and other risk factors are discussed in the Risk Factors section of its most recent annual report on Form 10-K, as updated in its most recent quarterly report on Form 10-Q, and in other documents filed with the SEC. If any of these risks materialize or if assumptions underlying forward-looking statements prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Statements may be identified by the use of words such as “we expect,” “are expected to be,” “estimate,” “plan,” “project,” “forecast,” “intend,” “anticipate,” “believe,” “seek,” ”will,” “targets,” “designed to,” “help accelerate” or other similar expressions. Forward-looking statements are made based on estimates and forecasts of financial and performance metrics, projections of market opportunity and current indications of customer interest, all of which are based on various assumptions. All such statements are based on current expectations of the management of Navitas and Microchip. Neither Microchip nor Navitas undertakes any obligation to update forward-looking statements to reflect events or circumstances after the date of this press release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d521aa42-41af-479c-bd1e-f276adec5b1f

• Non-dilutive transaction retires $87.8 million in asset-backed financing with no new equity issued; Duos and Axe Compute to expedite additional SPV site developments
• Axe Compute’s AI Cluster Customer Agreement Extended to Five Years

PITTSBURGH, Oct. 05, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU) today announced that it completed its acquisition from Duos Technologies Group, Inc. (“Duos”) of 100% of the special purpose vehicle (the “SPV”) that owns the Axe Compute AI cluster in Columbus, Georgia (the “Georgia Cluster”) on September 30, 2026. At closing, Axe Compute paid off the SPV’s asset-backed loan facility of approximately $87.8 million, with no new equity issued. The remaining consideration consists of a $42.9 million deferred purchase price payable to Duos in monthly installments of $715,000, with any unpaid balance due in full by the earlier of twelve months after signing and the date Axe Compute enters into a financing secured by the Georgia Cluster. Axe Compute expects to pay the deferred purchase price directly from cash flows generated by the Georgia Cluster. Axe Compute expects to generate approximately $364.6 million in revenue over the life of the customer agreement, with a significant expected improvement to estimated contract gross margin. In addition, the Georgia AI Cluster customer agreement has been extended from three years to five years, running through 2031 with renewal options thereafter.

Under a separate agreement, Duos covers the facility’s colocation and energy costs for the full five-year term, so the Georgia Cluster’s power and facility costs are fixed for the life of the customer contract. Duos continues to own and operate the Georgia facility.

Located at Duos’ facility in Columbus, Georgia, the Georgia Cluster consists of 288 servers containing 2,304 NVIDIA B300 GPUs. This Georgia Cluster is a landmark deployment and demonstrates Axe Compute’s program for designing, deploying, owning and operating dedicated AI infrastructure for enterprise customers. Axe Compute intends to apply the same structure to future deployments under the program: a committed customer, infrastructure secured for the same term, and ownership of the compute hardware.

“In another validation of our partnership with Duos, we are taking this step so we can both focus on what we do best. Duos is a world class data center builder and we are fortunate to call them a partner,” said Christopher Miglino, Chief Executive Officer of Axe Compute. “Our customer is committed for five years, our power and facility costs are covered for five years, and we own our GPUs. That alignment is expected to significantly expand the margin profile and return on this existing cluster.”

“This is the right move for both companies, and our relationship with Axe Compute has never been stronger,” said Doug Recker, Chief Executive Officer of Duos Technologies Group. “It streamlines the Georgia structure so Axe Compute can focus on what it does exceptionally well, delivering AI clusters to its customers. Duos stays focused on what we do best, providing the power and infrastructure behind them, now under a five-year partnership.”

Details of the acquisition are provided in a Current Report on Form 8-K filed by Axe Compute with the U.S. Securities and Exchange Commission.

About Axe Compute Inc.
Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure platform built on a fundamental premise: AI innovation should not be constrained by hardware choice or availability. The company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models. Axe Compute provides the design, deployment, ownership, and operation of large-scale, dedicated AI infrastructure worldwide, supported by enterprise-grade SLAs and operational expertise. For more information, visit www.axecompute.com.

About Duos Technologies Group, Inc.
Duos Technologies Group, Inc. (NASDAQ: DUOT), headquartered in Jacksonville, Florida, provides and manages modular architecture colocation data centers and infrastructure solutions. Through its Duos Edge AI brand, the Company delivers high-performance computing infrastructure built on its proprietary, scalable Duos Modular Architecture, designed to support the high-power environments required for AI and enterprise computing. Separately, Duos Technology Solutions provides manufacturer-agnostic sourcing and fulfillment services that enable efficient deployment of data centers and IT environments. Together, these platforms position the Company to address growing demand for distributed digital infrastructure in underserved Tier 3 and Tier 4 markets. For more information, visit www.duostech.com and www.duosedge.ai.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the transaction and the extended customer and power and facility agreements; the expected profitability, including impacts to estimated contract gross margin, and contracted revenue of the Georgia Cluster; Axe Compute’s ability to pay or refinance the deferred purchase price, including by use of cash flows generated by the Georgia Cluster or upon its accelerated maturity; the security interest held by Duos in the Georgia Cluster pending payment of the deferred purchase price; Axe Compute’s reliance on Duos and third-party service providers for facility, power and operational services; the application of the same structure to future deployments; the availability of power and facility capacity; the timing of deployment and customer delivery of the Georgia Cluster; the commencement, timing, deployment and activation of contracted customer projects; deployment and operational capabilities; customer demand; and the company’s ability to design, deploy, own and operate dedicated AI infrastructure at scale. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Axe Compute undertakes no obligation to update or revise forward-looking statements except as required by applicable law.

Media and Investor Relations Contact
Erin McMahon, CMO and Head of Investor Relations
ir@axecompute.com

Transaction Establishes New Structural Line of Business, Adding One of the Largest Independent Structural Steel Fabrication and Erection Platforms in the U.S.

HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — IES Holdings, Inc. (“IES”) (NASDAQ: IESC) today announced the closing of its previously announced acquisition of DBM Global Inc. (“DBM Global”), a vertically integrated structural steel fabrication, erection and industrial construction and engineering services platform, for total consideration of approximately $691 million, consisting of cash and shares of IES common stock. IES acquired 100% of the common stock of DBM Global, including the approximately 91.2% interest held by INNOVATE Corp. (“INNOVATE”) (NYSE: VATE) and the remaining interests held by other DBM Global stockholders. Effective today, DBM Global will operate as IES’s new Structural line of business alongside IES’s existing Communications, Residential, Infrastructure Solutions, and Commercial & Industrial segments. DBM Global generated revenue of approximately $1.5 billion for the twelve months ended June 30, 2026.

“Today we welcome DBM Global’s approximately 4,000 employees to IES,” said Matt Simmes, President and Chief Executive Officer of IES. “DBM Global brings scaled engineering, fabrication and erection capabilities and a long track record of successfully delivering complex structural projects. We are also excited to work with DBM Global to offer a broader range of products and services so that together we deliver innovative solutions to our combined customer base, particularly in data center, industrial and infrastructure markets. We look forward to investing in DBM Global’s people, facilities and equipment and to working together on our customers’ most complex projects.”

“DBM Global is a premier business with an outstanding team and substantial long-term growth potential, and we believe it will be an excellent addition to IES’s portfolio of businesses,” said Jeff Gendell, Executive Chairman of IES. “As our largest acquisition to date, we were deliberate in how we financed the transaction, with a focus on maintaining our strong balance sheet by using a combination of cash, borrowings and IES equity. We expect substantial cash flow from both IES and DBM Global will allow us to rapidly repay acquisition-related borrowings while continuing to reinvest in our businesses and pursue additional opportunities.”

Rustin Roach, President and Chief Executive Officer of DBM Global, added, “Joining IES marks an exciting next chapter for our businesses and our people. IES’s long-term ownership approach and financial strength will allow us to accelerate investment in our operations while continuing to deliver for our customers, many of whom we have served for decades. We look forward to working alongside IES’s other operating segments to bring additional capabilities and capacity to our customers’ projects.”

Total consideration of approximately $691 million consisted of approximately $545 million in cash and 430,974 shares of IES common stock (as adjusted for IES’s two-for-one stock split effected on August 21, 2026) valued at approximately $146 million based on the closing price of IES common stock on October 2, 2026, subject to customary net working capital and other post-closing adjustments. The cash consideration includes a $35 million payment to INNOVATE in respect of the estimated cost to INNOVATE of participating in a joint election under Section 338(h)(10) of the Internal Revenue Code. IES funded the cash consideration with cash on hand and borrowings under its amended and expanded credit facility arranged by Wells Fargo.

Headquartered in Phoenix, Arizona, DBM Global operates through a family of established brands, including Schuff Steel, Banker Steel, GrayWolf, DBM Vircon and Aitken, with more than 2 million square feet of fabrication and operating facilities across the United States. DBM Global provides structural steel fabrication, erection and industrial construction and engineering services across commercial, industrial, data center, stadium and infrastructure end markets and has supplied structural steel and erection services to many of the country’s most recognizable projects.

About IES Holdings, Inc.
IES designs and installs integrated electrical and technology systems, provides infrastructure solutions and services, and delivers structural steel engineering, fabrication and erection to a variety of end markets, including data centers, residential housing, and commercial, industrial and infrastructure facilities. Our more than 16,000 employees serve clients primarily in the United States. For more information about IES, please visit www.ies-co.com.

Company Contact:
Tracy McLauchlin, Chief Financial Officer
IES Holdings, Inc.
(713) 860-1500

Investor Relations Contact:
Robert Winters
Alpha IR Group
(312) 445-2870
IESC@alpha-ir.com

Certain statements in this release may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, all of which are based upon various estimates and assumptions that IES believes to be reasonable as of the date hereof. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “seek,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology. These statements involve risks and uncertainties that could cause IES’s actual future outcomes to differ materially from those set forth in such statements. Such risks and uncertainties include, but are not limited to, a general reduction in the demand for our products or services; changes in general economic conditions, including supply chain constraints, high rates of inflation, changes in consumer sentiment, elevated interest rates, and market disruptions resulting from a number of factors, including geo-political events; competition in the industries in which we operate, which could result in the loss of one or more customers or lead to lower margins on new projects; the use of estimates in placing bids on fixed price contracts, variations from estimated contract costs and our ability to successfully manage and execute projects, the cost and availability of qualified labor and the ability to maintain positive labor relations, and our ability to pass along increases in the cost of commodities used in our business; our ability to enter into, and the terms of, future contracts; the existence of a small number of customers from whom we derive a meaningful portion of our revenues; reliance on third parties, including subcontractors and suppliers, to complete our projects; the inability to carry out plans and strategies as expected, including the inability to identify and complete acquisitions that meet our investment criteria, or the subsequent underperformance of those acquisitions; challenges integrating new businesses into IES or new types of work, products or processes into our segments; backlog that may not be realized or may not result in profits; failure to adequately recover on contract change orders or claims against customers; closures or sales of our facilities resulting in significant future charges or a significant disruption of our operations; the impact of future epidemics or pandemics on our business; an increased cost of surety bonds affecting margins on work and the potential for our surety providers to refuse bonding or require additional collateral at their discretion; the impact of seasonality, adverse weather conditions, and climate change; fluctuations in operating activity due to factors such as cyclicality, downturns in levels of construction or the housing market, and differing regional economic conditions; difficulties in managing our billings and collections; accidents resulting from the physical hazards associated with our work and the potential for accidents; the possibility that our current insurance coverage may not be adequate or that we may not be able to obtain policies at acceptable rates; the effect of litigation, claims and contingencies, including warranty losses, damages or other latent defect claims in excess of our existing reserves and accruals; costs and liabilities under existing or potential future laws and regulations, including those laws and regulations related to the environment and climate change, as well as the inability to transfer, renew and obtain electrical and other professional licenses; interruptions to our information systems and cyber security or data breaches; expenditures to conduct environmental remediation activities required by certain environmental laws and regulations; loss of key personnel, ineffective transition of new management, or general labor constraints; credit and capital market conditions, including changes in interest rates that affect the cost of construction financing and mortgages, and the inability of some of our customers to obtain sufficient financing at acceptable rates, which could lead to project delays or cancellations; limitations on our ability to access capital markets and generate cash from operations to fund our capital needs; the impact on our effective tax rate or cash paid for taxes from changes in tax positions we have taken or changes in tax laws; difficulty in fulfilling the covenant terms of our revolving credit facility, which could result in a default and acceleration of any indebtedness under such revolving credit facility; reliance on certain estimates and assumptions that may differ from actual results in the preparation of our financial statements and the impacts of new accounting, control and operating procedures resulting from new accounting pronouncements; uncertainties inherent in the use of percentage-of-completion accounting, which could result in the reduction or elimination of previously recorded revenues and profits; the recognition of potential goodwill, long-lived assets and other investment impairments; the existence of a controlling shareholder, who has the ability to take action not aligned with other shareholders or to dispose of all or a significant portion of the shares of our common stock it holds, which may trigger certain change of control provisions in a number of our material agreements; the relatively low trading volume of our common stock, which could increase the volatility of our stock price and could make it more difficult for shareholders to sell a substantial number of shares for the same price at which shareholders could sell a smaller number of shares; the possibility that we issue additional shares of common stock, preferred stock or convertible securities that will dilute the percentage ownership interest of existing stockholders and may dilute the value per share of our common stock; the potential for substantial sales of our common stock, which could adversely affect our stock price; the impact of increasing scrutiny and changing expectations from investors and customers, or new or changing regulations, with respect to climate change or environmental impacts of our operations; the cost or effort required for our shareholders to bring certain claims or actions against us, as a result of our designation of the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings; and the possibility that our internal controls over financial reporting and our disclosure controls and procedures may not prevent all possible errors that could occur, as well as other risk factors discussed in this document, in IES’s annual report on Form 10-K for the year ended September 30, 2025 and in IES’s other reports on file with the SEC. You should understand that such risk factors could cause future outcomes to differ materially from those experienced previously or those expressed in such forward-looking statements. IES undertakes no obligation to publicly update or revise any information or any forward-looking statements to reflect events or circumstances that may arise after the date of this release.

Forward-looking statements are provided in this press release pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995 and should be evaluated in the context of the estimates, assumptions, uncertainties, and risks described herein.

General information about IES Holdings, Inc. can be found at http://www.ies-co.com under “Investor Relations.” IES’s annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, as well as any amendments to those reports, are available free of charge through IES’s website as soon as reasonably practicable after they are filed with, or furnished to, the SEC.

RESTON, Va., Oct. 05, 2026 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC), a leading mission integrator supporting defense, space, intelligence, and civilian agencies, today announced it has completed the acquisition of Information Security Corporation (ISC).

For more than three decades, ISC has delivered public key infrastructure (PKI), encryption, and credential management software to some of the most security-conscious organizations in government and industry, providing the critical cryptographic building blocks for confidentiality, integrity, and availability of sensitive data. Engineered with a forward-looking focus on automation and crypto-agility, ISC’s product suite helps customers modernize their cryptographic infrastructure and transition to post-quantum cryptography. The suite spans PKI and data protection solutions, including CertAgent, which has been on the National Security Agency’s Commercial Solutions for Classified (CSfC) Components List for more than a decade.

“This strategic tuck-in acquisition reflects our disciplined approach to investing in technology and capabilities that address the nation’s most critical challenges,” said Jim Reagan, Chief Executive Officer of SAIC. “Integrating ISC’s mission-proven cryptographic technologies with SAIC’s pedigree of delivering and operating robust zero-trust architectures, provides our intelligence and defense customers with the security and scalability to protect against rapidly evolving threats.”

“Joining SAIC marks an exciting new chapter for ISC and our employees,” said Jonathan Schulze-Hewett, Vice President of Development at ISC. “For more than three decades, our team has built innovative products to solve some of our customers’ most difficult security challenges. Joining SAIC gives us the opportunity to build on that work and bring ISC’s technology to more customers and more missions.”

ISC’s technology is deeply embedded across the U.S. intelligence community and Department of War, supporting identity, authentication, and data protection in some of the government’s most sensitive environments.

Financial terms were not disclosed. SAIC was supported by KPMG and ISC was advised by TideLock Partners.

About SAIC
SAIC^® is a premier mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, intelligence, and civilian markets includes secure high-end solutions in mission IT, enterprise IT, engineering services, and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.

We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

Media Contact: 
Caralyn Duke
publicrelations@saic.com

Forward-Looking Statements
Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at www.saic.com or on the SEC’s website at www.sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — INNOVATE CORP.^® (NYSE: VATE) (“INNOVATE”) announced today that it has completed the previously announced sale of DBM Global, Inc. (“DBMG”) to IES Holdings, Inc. (Nasdaq: IESC) (“IES”) pursuant to the Transaction Agreement (the “Agreement”) announced on August 10, 2026 (the “Transaction”).

“Closing this transaction is a significant milestone for INNOVATE,” said Paul Voigt, Interim CEO of INNOVATE. “With these proceeds, we are substantially reducing our debt and strengthening INNOVATE’s balance sheet, which improves our financial flexibility as we focus on our remaining businesses. We want to thank Rustin Roach and his world-class team for their years of dedicated service and the tremendous value they have built. We wish Rustin and the team continued success as part of IES. INNOVATE’s remaining businesses are well positioned in attractive end markets, and we remain focused on executing our strategy, enhancing shareholder value and building on this momentum.”

Transaction Details

Under the terms of the Agreement, IES has acquired 100% of the outstanding shares of DBMG common stock — including approximately 91.21% previously held by INNOVATE (through DBM Global Intermediate Holdco Inc.) and the remaining approximately 8.79% previously held by other DBMG stockholders.

Consideration received by INNOVATE and DBM Global Intermediate Holdco Inc. (together, “Seller”) consisted of Seller’s approximately 91.21% pro rata share of the base purchase price, as adjusted at closing based on estimates of cash, working capital, indebtedness and transaction expenses of DBMG and certain additional adjustments as set forth in the Agreement. The purchase price remains subject to finalization following delivery of a post-closing statement and, if necessary, resolution of any disputes through an independent accounting firm. At closing, Seller received (subject to post-closing adjustments):

• approximately $378 million in cash, representing Seller’s portion of the $510 million cash consideration after giving effect to Seller’s receipt of 100% of the IES common stock issued as part of the total consideration and closing adjustments; and
• 430,974 shares of IES common stock (as adjusted for IES’s two-for-one stock split effected on August 21, 2026), valued at approximately $146 million based on the closing price of IES common stock on October 2, 2026.

The stock consideration is subject to a maximum 60-day lock-up period following the closing of the Transaction, subject to terms of the Agreement.

Each of the other DBMG stockholders will be entitled to receive its pro rata share of the base purchase price, subject to customary adjustments, entirely in cash.

In addition, Seller received $35 million in cash at closing as compensation for costs and obligations to be borne by Seller in connection with the joint tax election under Section 338 of the Internal Revenue Code being made with respect to the Transaction. Including this payment, Seller received total cash of approximately $413 million at closing.

Use of Proceeds

INNOVATE intends to use all net proceeds from the Transaction to reduce its outstanding debt.

For more information, please refer to the Current Report on Form 8-K to be filed by INNOVATE with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the completion of the Transaction.

You may obtain copies of all documents filed by INNOVATE with the SEC regarding this transaction, free of charge, at the SEC’s website, www.sec.gov or from INNOVATE’s website at https://www.innovate-ir.com/.

Advisors

Cleary Gottlieb Steen & Hamilton LLP served as legal advisor to INNOVATE in connection with the Transaction. Jefferies served as financial advisor to INNOVATE.

About INNOVATE

INNOVATE is a holding company that owns, operates and invests in a portfolio of best-in-class businesses in the Life Sciences and Spectrum markets. INNOVATE is focused on maximizing value through disciplined capital allocation, strategic oversight and operational support of its subsidiaries. For more information, please visit: http://www.innovatecorp.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements generally relate to future events, including statements regarding post-closing adjustments to the purchase price under the Agreement; the value of the IES common stock received by INNOVATE and INNOVATE’s plans with respect to such stock; INNOVATE’s intended use of the net proceeds of the Transaction and its expected levels of indebtedness; and INNOVATE’s strategies with respect to its capital structure and its remaining businesses. You are cautioned that such statements are not guarantees of future performance and that INNOVATE’s actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause INNOVATE’s actual results to differ materially from these forward-looking statements include, but are not limited to (i) the outcome of post-closing purchase price adjustments, including any resolution of disputes under the Agreement; (ii) fluctuations in the market price of IES common stock, including during the lock-up period; (iii) INNOVATE’s ability to complete planned debt repayments on anticipated terms and timing; (iv) the performance of INNOVATE’s remaining businesses following the Transaction; (v) macroeconomic conditions; and (vi) the other factors under the heading “Risk Factors” set forth in INNOVATE’s Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are available on INNOVATE’s website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date of this press release. INNOVATE undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.

INNOVATE Investor Contact:
Solebury Strategic Communications
Jenna Kozlowski
(212) 235-2691
Email: ir@innovatecorp.com

ATLANTA, Oct. 05, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today announced that it has been awarded a task order to design, develop, and pilot a data governance framework for secure access to controlled biomedical research data by the National Institutes of Health (“NIH”).

Under this task order, DLH will serve as a technical advisor to harmonize NIH and federal data policies and integrate governance workflows across biomedical data platforms, piloting a data management approach within the National Heart, Lung, and Blood Institute (“NHLBI”) and at least one other NIH Institute or Center which could serve as a roadmap for NIH-wide adoption.​ DLH will incorporate security, privacy, data rights, and artificial intelligence (“AI”) governance requirements where applicable, and collect performance metrics related to usability, compliance, interoperability, and stakeholder satisfaction.

“This award expands our role as a technical and strategic advisor to NIH and brings together DLH’s expertise in biomedical research, data governance, and secure digital solutions,” said Brooke Pierce, President of DLH’s Health business group. “We believe this work will strengthen our foundation for pursuing future enterprise-scale modernization opportunities as NIH evaluates broader adoption of the framework.”

This task order represents new work for DLH and has a total value of $2 million over an eighteen-month period of performance.

About DLH

DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com.

Contact Information:

Investor Relations

investorrelations@dlhcorp.com

Media

communications@dlhcorp.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding expected contract performance, future task order value, and anticipated operational benefits. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities; legal, regulatory, and political changes from the federal government that could result in economic uncertainty; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.

Government of Greenland formally approves the Tanbreez Mining Plan and Closure Plan for one of the world’s largest heavy rare earth deposits – 19 critical elements approved, including the heavy rare earths terbium, dysprosium and yttrium and the magnet metals neodymium and praseodymium – with activity-specific operating permits the final step before construction

Key Highlights

• Government Green Light Through 2050: The Government of Greenland has approved the Mining Plan and Closure Plan for the Company’s flagship Tanbreez Project, establishing a clear, long-term framework to build, operate and ultimately rehabilitate the mine through September 2050 – approximately 24 years of permitted operations under the Company’s existing exploitation licence.
• 19 Critical Elements Approved for Extraction: The approvals cover the heavy rare earths terbium, dysprosium and yttrium, the magnet metals neodymium and praseodymium, and the strategic metals zirconium, hafnium, tantalum and niobium – materials essential to electric vehicles, wind turbines, advanced electronics and defense systems, and among the most supply-constrained critical minerals in Western markets.
• Major De-Risking Step Toward Construction: With the Mining and Closure Plans approved, the remaining gate to construction is the activity-specific operating permits under sections 120 and 121 of the Greenland Mineral Activities Act. The approvals give investors and prospective financing partners significantly greater clarity on the path to developing a Western-aligned source of heavy rare earths.

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals exploration and mining company, today announced that the Government of Greenland (Naalakkersuisut) has formally approved the Mining Plan and Closure Plan for the Company’s flagship Tanbreez Project in Southern Greenland – one of the world’s largest heavy rare earth deposits. The approvals build on the exploitation licence granted to Tanbreez in 2020 and set out how the mine will be built, operated and ultimately closed and rehabilitated over a period running through 2050.

The approvals were granted to the Company’s Greenlandic subsidiary, Tanbreez Mining Greenland A/S, under sections 77 and 80 of the Greenland Parliament Act on Mineral Activities and Exclusive Licence No. 2020-54, which covers the exploitation of minerals at Killavaat Alannguat, between Narsaq and Qaqortoq in Southwest Greenland. They were signed on behalf of the Government of Greenland by Múte B. Egede, Minister for Foreign Affairs, Business and Mineral Resources, in Nuuk on September 29, 2026.

Scope of the Approvals

The approvals cover the period from signing until September 8, 2050, and set out the 19 elements the Company may extract at Tanbreez once the remaining operating permits are in place: zirconium, hafnium, tantalum, niobium, lanthanum, cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium and yttrium.

Of particular significance, the approved elements include the heavy rare earths terbium, dysprosium and yttrium – among the scarcest and most strategically important rare earths, used in high-temperature permanent magnets for electric vehicle motors, wind turbines and defense applications – together with the magnet metals neodymium and praseodymium.

The Mining Plan sets out how the Company will build and operate the mine, processing facilities, port and supporting infrastructure at Tanbreez. The Closure Plan sets out how the site will be decommissioned and rehabilitated at the end of its life, reflecting the Company’s commitment to responsible development in partnership with the Government of Greenland and the communities of South Greenland.

Tony Sage, Chairman and Chief Executive Officer of Critical Metals Corp, commented:
“Approval of the Mining and Closure Plans is a defining milestone for Tanbreez and for Critical Metals Corp. It gives us a clear framework through 2050 to responsibly develop one of the world’s largest heavy rare earth deposits, in partnership with the Government of Greenland and the communities of South Greenland. We thank the Government and the Mineral Resources Authority for their thorough review, and we now move forward with the specific operating permits that will take us to construction.”

Michael Hanson, Independent Director of Critical Metals Corp, added:
“The approval of the Mining and Closure Plans is an important step in de-risking Tanbreez. It gives investors and potential financing partners greater clarity on the path to development of one of the most significant rare earth projects outside of established supply chains.”

Path to Construction

The next step is to obtain the operating permits for specific activities at Tanbreez under sections 120 and 121 of the Act, covering areas including environmental management, marine transport, health and safety, and the export and sale of minerals. Construction can begin once these permits are granted and the required financial security is in place. The Company will provide further updates as these approvals progress.

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next-generation technologies for Europe and its Western world partners. Its flagship Project, Tanbreez, is one of the world’s largest rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations, including with respect to the development of the Tanbreez Project, the receipt of specific approvals and operating permits, and the anticipated timing of construction and production. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: ir@criticalmetalscorp.com
Media: pr@criticalmetalscorp.com

LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2026 meeting being held November 6-11, 2026 in Orlando, Florida. Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster on November 10.

Abstract: 2216
Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I CARLYSLE Study
Session date and time: Tuesday, November 10, 2026; 10:30 AM–12:30 PM ET

Summary: Updated data will include safety and efficacy results from the Phase I CARLYSLE study with up to 20 months follow-up in adult patients and ≥3 months follow-up in adolescent patients.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

INDICATION
AUCATZYL^® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS) occurred in patients receiving AUCATZYL. Do not administer AUCATZYL to patients with active infection or inflammatory disorders. Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage CRS. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including fatal and life-threatening reactions, occurred in patients receiving AUCATZYL, including concurrently with CRS or after CRS resolution. Monitor for neurologic signs and symptoms after treatment with AUCATZYL. Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage neurologic toxicities. Provide supportive care and/or corticosteroids, as needed. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies.

WARNINGS AND PRECAUTIONS

Cytokine Release Syndrome (CRS)
Cytokine Release Syndrome (CRS) occurred following treatment with AUCATZYL. CRS was reported in 75% (75/100) of patients including Grade 3 CRS in 3% of patients. The median time to onset of CRS was 8 days following the first infusion (range: 1 to 23 days) with a median duration of 5 days (range: 1 to 21 days). The most common manifestations of CRS included fever (100%), hypotension (35%), and hypoxia (19%).

Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage CRS. During and following treatment with AUCATZYL, closely monitor patients for signs and symptoms of CRS daily for at least 14 days at the healthcare facility following the first infusion. Continue to monitor patients for CRS for at least 4 weeks following each infusion with AUCATZYL. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, immediately evaluate the patient for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.

Neurologic Toxicities
Neurologic toxicities including Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), which were fatal or life-threatening, occurred following treatment with AUCATZYL. Neurologic toxicities were reported in 64% (64/100) of patients, including Grade ≥ 3 in 12% of patients. The median time to onset of neurologic toxicities was 10 days (range: 1 to 246 days) with a median duration of 13 days (range: 1 to 904 days). Among patients with neurologic toxicities, the most common symptoms (> 5%) included ICANS (38%), headache (34%), encephalopathy (33%), dizziness (22%), tremor (13%), anxiety (9%), insomnia (9%), and delirium (8%).

Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
ICANS events occurred in 24% (24/100) of patients, including Grade ≥ 3 in 7% (7/100) of patients. Of the 24 patients who experienced ICANS, 33% (8/24) experienced an onset after the first infusion, but prior to the second infusion of AUCATZYL.

The median time to onset for ICANS events after the first infusion was 8 days (range: 1 to 10 days) and 6.5 days (range: 2 to 22 days) after the second infusion, with a median duration of 8.5 days (range: 1 to 53 days).

Eighty-eight percent (21/24) of patients received treatment for ICANS. All treated patients received high-dose corticosteroids and 42% (10/24) of patients received anti-epileptics prophylactically. Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage ICANS.

Counsel patients to seek medical attention should signs or symptoms of neurologic toxicity/ ICANS occur. At the first sign of Neurologic Toxicity /ICANS, immediately evaluate patients for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.

Effect on Ability to Drive and Use Machines
Due to the potential for neurologic events, including altered mental status or seizures, patients receiving AUCATZYL are at risk for altered or decreased consciousness or coordination in the eight weeks following AUCATZYL infusion or until resolution of the neurological event by the treating physician. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.

Prolonged Cytopenias
Patients may exhibit cytopenias including anemia, neutropenia, and thrombocytopenia for several weeks after treatment with lymphodepleting chemotherapy and AUCATZYL. In patients who were responders to AUCATZYL, Grade ≥ 3 cytopenias that persisted beyond Day 30 following AUCATZYL infusion were observed in 71% (29/41) of patients and included neutropenia (66%, 27/41) and thrombocytopenia (54%, 22/41). Grade 3 or higher cytopenias that persisted beyond Day 60 following AUCATZYL infusion was observed in 27% (11/41) of patients and included neutropenia (17%, 7/41) and thrombocytopenia (15%, 6/41). Monitor blood counts after AUCATZYL infusion.

Infections
Severe, including life-threatening and fatal infections occurred in patients after AUCATZYL infusion. Non-COVID-19 infections of all grades occurred in 67% (67/100) of patients. Grade 3 or higher non-COVID-19 infections occurred in 41% (41/100) of patients. AUCATZYL should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after AUCATZYL infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines.
Grade 3 or higher febrile neutropenia was observed in 26% (26/100) of patients after AUCATZYL infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.
Viral reactivation, potentially severe or life-threatening, can occur in patients treated with drugs directed against B cells. There is no experience with manufacturing AUCATZYL for patients with a positive test for human immunodeficiency virus (HIV) or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV). Perform screening for HBV, HCV and HIV in accordance with clinical guidelines before collection of cells for manufacturing.

Hypogammaglobulinemia
Hypogammaglobulinemia and B-cell aplasia can occur in patients after AUCATZYL infusion. Hypogammaglobulinemia was reported in 10% (10/100) of patients treated with AUCATZYL including Grade 3 events in 2 patients (2%).
Immunoglobulin levels should be monitored after treatment with AUCATZYL and managed per institutional guidelines including infection precautions, antibiotic or antiviral prophylaxis, and immunoglobulin replacement.
The safety of immunization with live viral vaccines during or following treatment with AUCATZYL has not been studied. Vaccination with live viral vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy treatment, during AUCATZYL treatment, and until immune recovery following treatment with AUCATZYL.

Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
HLH/MAS including fatal and life-threatening reactions occurred after treatment with AUCATZYL. HLH/MAS was reported in 2% (2/100) of patients and included Grade 3 and Grade 4 events with a time of onset at Day 22 and Day 41, respectively. One patient experienced a concurrent ICANS events after AUCATZYL infusion and died due to sepsis with ongoing HLH/MAS that had not resolved. Administer treatment for HLH/MAS according to institutional standards.

Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO), an excipient used in AUCATZYL. Observe patients for hypersensitivity reactions during and after AUCATZYL infusion.
Secondary Malignancies
Patients treated with AUCATZYL may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Autolus at 1-855-288-5227 for reporting and to obtain instructions on the collection of patient samples for testing.

Adverse Reactions
The safety of AUCATZYL was evaluated in the FELIX study in which 100 patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) received AUCATZYL at a median dose of 410 × 10⁶ CD19 CAR-positive viable T cells (range: 10 to 480 × 10⁶ CD19 CAR-positive viable T cells with 90% of patients receiving the recommended dose of 410 × 10⁶ +/- 25%).

The most common serious adverse reactions of any Grade (incidence ≥ 2%) included infections-pathogen unspecified, febrile neutropenia, ICANS, CRS, fever, bacterial infectious disorders, encephalopathy, fungal infections, hemorrhage, respiratory failure, hypotension, ascites, HLH/MAS, thrombosis and hypoxia. Nine patients (9%) experienced fatal adverse reactions which included infections (sepsis, pneumonia, peritonitis), ascites, pulmonary embolism, acute respiratory distress syndrome, HLH/MAS and ICANS. Of the 9 patients, five patients who died from infections had pre-existing and ongoing neutropenia prior to receiving bridging therapy, lymphodepletion chemotherapy treatment and/or AUCATZYL.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Forward-Looking Statements  
his press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding Autolus’ future expectations, plans and prospects, including the therapeutic potential and expected clinical benefits of obe-cel; in SLE and LN; the development of obe-cel in autoimmune indications and of additional product candidates, including statements regarding the initiation, timing, progress and results of clinical studies or trials and related preparatory work; expectations regarding regulatory interactions, regulatory pathways and potential accelerated approval pathways; and the period during which the results of clinical studies or trials will become available. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks identified in the section titled “Risk Factors” in Autolus’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC), on March 26, 2026 and its subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the SEC. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing Autolus’ views as of any date subsequent to the date of this press release.

Contact:  

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

Integration agreement enables Malam to integrate Zorronet technology into large-scale customer projects across Israel

NETANYA, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — Zorronet Ltd. (“Zorronet”), a wholly owned subsidiary of Tessera Defense and Homeland Security Inc. (“Tessera” or the “Company”) (NYSE American:HLSQ), today announced the signing of a 24-month framework subcontracting agreement with Team-Netcom Ltd., a wholly owned subsidiary of Malam Team Ltd. (“Malam”), one of Israel’s top five largest IT services groups. The agreement will see Malam incorporate Zorronet’s AI-powered security orchestration technology as a preferred vendor for projects for customers across Israel.

Under the agreement, Team-Netcom Ltd. will serve as the prime contractor and systems integrator, managing project delivery, customer implementation and integration with existing systems. Zorronet will provide the AI intelligence layer that connects cameras, sensors and other security systems, understands activity in real time, validates relevant events and helps coordinate the response. The technology also supports object detection and classification across security, safety, vehicle, fire and smoke-related scenarios.

With approximately 5,700 technology specialists, Malam-Team Group is one of Israel’s largest technology groups, with capabilities spanning systems integration, communications, cloud, cyber, municipal solutions, transportation and defense. Its experience delivering complex projects for government, critical infrastructure and enterprise customers nationwide, gives the collaboration a strong foundation for enabling customers to add more advanced security capabilities across a wide range of sites and applications.

The agreement enables Zorronet’s technology to be deployed within larger Malam-led projects without requiring customers to replace existing security infrastructure. For organizations whose existing camera networks are still used primarily for monitoring and recording, Zorronet adds an intelligence layer that turns those systems into sources of real-time awareness. Zorronet can connect with installed cameras, VMS platforms and other security systems to provide a unified intelligence layer for real-time understanding, event validation and coordinated response. The offering also includes Zorronet’s own video management capabilities and will be available primarily through a SaaS model, with an on-premises option for customers that require local processing.

Specific projects under the 24-month framework agreement will be carried out through individual work orders agreed between Malam and Zorronet. The parties also intend to pursue additional projects together and to evaluate, in good faith, opportunities to expand the scope of their collaboration over time.

The companies intend to operate a tiered support model backed by a back-to-back service level agreement. Malam will provide implementation and front-line customer support, including help desk services and subject-matter expertise, while Zorronet’s engineering teams will provide development-level support, software fixes and version updates.

“We see significant value in working with a Tier 1 integrator that understands both the technology and the practical requirements of large customer deployments,” said Idan Wasserman, CEO of Zorronet. “That integration expertise is important because customers increasingly want to improve the systems they already have rather than replace them. Together, we can give customers a more straightforward path to adding advanced analytics and orchestration to their existing systems, helping them identify and validate relevant events, make better use of their current infrastructure, and build additional capabilities over time.”

“This agreement demonstrates an important route to market for Zorronet,” said Roy Timor-Rousso, CBO of Tessera. “By working with a Tier 1 systems integrator of Malam’s scale, Zorronet can bring its technology into larger customer projects while leveraging Malam’s existing integration, delivery and support capabilities. Becoming a preferred vendor within that framework strengthens Zorronet’s ability to participate in projects across a broad range of customer environments. The model enables each company to focus on what it does best, and we look forward to building on this collaboration as projects move forward.”

About Zorronet Ltd.

Zorronet Ltd., a Tessera company, develops AI-powered operational intelligence and command-and-control technology that connects cameras, sensors, drones, IoT devices and other field systems into a unified real-time operating picture. The platform enables organizations to bring together information, operational workflows and communications across multiple systems and locations, supporting both centralized control rooms and distributed teams in the field.

Zorronet combines its software platform with systems integration, communications infrastructure and operational deployment capabilities, enabling the Company to support projects from initial characterization and planning through implementation, commissioning and ongoing operations. Its technologies and capabilities are applicable across defense, homeland security, critical infrastructure, transportation, municipalities, agriculture, smart cities, test and evaluation environments, remote asset protection and civilian security applications.

About Tessera Defense and Homeland Security Inc. (Formerly BiomX Inc.)

Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) is a physical security technology company providing integrated, bespoke security solutions that connect detection, intelligence and response across complex security environments. The Tessera platform integrates cameras, sensors, detection technologies, AI and other security infrastructure to identify threats, understand events and coordinate response in real time. Tessera provides the technology, hardware and implementation expertise needed to tailor security solutions to the specific requirements of each site, helping customers deploy and optimize integrated security systems across critical infrastructure, energy, digital infrastructure and homeland security applications.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words such as “expects,” “intends,” “plans,” “believes,” “will,” “may,” “anticipates,” “estimates” and similar expressions. These statements are based on the Company’s current expectations and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied.

These risks and uncertainties include, among others, the ability of Zorronet and Malam Team to successfully implement and execute the framework agreement described herein; the ability of the parties to identify, secure and successfully complete customer projects under the framework agreement; the timing, scope and value of any work orders that may be issued under the framework agreement; the ability of Zorronet’s technology to meet the technical, security, integration, performance and other requirements of Malam Team and its customers; Zorronet’s ability to successfully integrate its technology with customers’ existing cameras, video management systems, sensors and other infrastructure; the ability of the parties to provide implementation, support and other services in accordance with the applicable service level requirements; the extent to which Zorronet’s preferred vendor status results in additional customer deployments, work orders, revenue or other commercial opportunities; the adoption of Zorronet’s technologies by Malam Team customers across municipal and public safety, transportation, government, critical infrastructure and other markets; Zorronet’s ability to expand its relationships with systems integrators and translate such relationships into broader commercial opportunities in Israel and internationally; the Company’s ability to execute its business plan for Zorronet and expand adoption of Zorronet’s technologies; the Company’s ability to raise additional capital and to execute its business and strategic initiatives; the risk that the Company may not regain compliance with the NYSE American continued listing standards within the plan period or at all; the risk that the Company may not make progress consistent with its plan; the possibility that the Company’s common stock may be suspended from trading or delisted from the NYSE American; the Company’s going concern qualification; and the other risks described in the Company’s filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 19, 2026, as supplemented by the Form 10-K/A filed with the SEC on April 30, 2026, the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the SEC on August 19, 2026 as well as the Company’s other filings with the SEC.

The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact

Yair Ohayon

Yairo@thlsq.ai

Repayment of Oak Street Funding Term Loan Eliminates Approximately $1 Million of Annual Principal, Interest and Fee Payments

LAKEWOOD, NJ, Oct. 05, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“Reliance,” “EZRA” or the “Company”), an InsurTech company leveraging artificial intelligence, cloud computing and advanced technologies to transform the insurance agency/brokerage industry, today announced that it has repaid in full its term loan with Oak Street Funding LLC, which was the Company’s only term debt. As a result of the repayment, the Company has no outstanding term debt. The term loan had an outstanding balance of approximately $4.4 million as of June 30, 2026. Following the repayment, the Company has more than $6 million of cash on its balance sheet.

The loan was repaid with approximately $1.2 million from the sale of Southwestern Montana Insurance Center, which closed on September 11, 2026, approximately $2.2 million from the sale of Altruis Benefit Consulting, which closed on September 24, 2026, and approximately $1.0 million of cash previously held as collateral for the loan.

Highlights

• Term debt retired. Following repayment of the Oak Street Funding term loan, the Company has retired 100% of its term debt.
• More than $6 million of cash. Even after the repayment, the Company has more than $6 million of cash on its balance sheet.
• Lower annual debt service. Repayment eliminates approximately $1 million of annual principal, interest and service fee payments, including approximately $400,000 of annual interest and service fees.
• Cash collateral applied. Approximately $1.0 million of cash previously held as collateral for the loan was applied toward the payoff.
• Funded by asset sales. The repayment was funded with proceeds from the Company’s sales of non-core agencies and cash previously held as loan collateral, without the issuance of any shares.

“Retiring our term debt has been a priority since we began monetizing our non-core agencies, and doing so this month strengthens our balance sheet in a meaningful way,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “With the loan repaid, more of our cash can go toward our AI platform and the RELI Exchange network, and we have greater flexibility as we plan the Company’s next stage of growth.”

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (Nasdaq: EZRA) is an InsurTech company leveraging artificial intelligence, cloud computing and advanced technologies to transform the insurance agency/brokerage industry. Through its growing portfolio of proprietary AI solutions and insurance operations, the Company is focused on enhancing operational efficiency, improving customer experiences and creating long-term shareholder value. Further information about the Company can be found at https://www.relianceglobalgroup.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical fact and may be identified by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “target,” “project,” “potential,” or similar expressions, or by discussions of strategy, plans or intentions. Forward-looking statements in this press release include, without limitation, statements regarding: the anticipated effects of the repayment of the Company’s term loan on its cash position, interest expense, liquidity, capital structure and financial flexibility; the Company’s intended use of cash; the Company’s portfolio monetization strategy; and the continued development, deployment and potential commercialization of the Company’s proprietary artificial intelligence platform and its RELI Exchange InsurTech platform.

These statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other factors, many of which are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may differ materially from those expressed or implied by these forward-looking statements.

Such risks and uncertainties include, without limitation: the Company’s ability to fund its operations and growth initiatives from existing cash and operating cash flow, and its potential need to raise additional capital, which may not be available on acceptable terms, or at all; the loss of the revenue and operating cash flow historically contributed by the divested agencies and the resulting impact on the Company’s consolidated results of operations; the risk that the Company is unable to redeploy capital into initiatives that generate the anticipated returns; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market; the development, deployment, market acceptance and potential commercialization of the Company’s proprietary artificial intelligence technologies; competition, regulatory developments and other risks affecting the insurance brokerage and InsurTech industries; and general business, economic, market and geopolitical conditions. Additional information regarding these and other factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission, copies of which are available free of charge at www.sec.gov.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: EZRA@crescendo-ir.com